about
The ReCaPTa study - a prospective out of hospital cardiac arrest registry including multiple sources of surveillance for the study of sudden cardiac death in the Mediterranean areaDiffering prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysisMagnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES RegistryLeft atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure.Association of blood pressure and its evolving changes with the survival of patients with heart failure.Risk stratification of mortality in patients with heart failure and left ventricular ejection fraction >35%.Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure.Octapolar electrocatheter for His bundle recording and sequential bedside electrophysiologic testing.Identification of very low risk chest pain using clinical data in the emergency department.Improving the management of non-ST elevation acute coronary syndromes: systematic evaluation of a quality improvement programme European QUality Improvement Programme for Acute Coronary Syndrome: the EQUIP-ACS project protocol and design.Percutaneous Retrieval of a Knotted Provisional Pacemaker Using Proximal Electrode Cut off and Distal End Snaring.Chronic total occlusion: To treat or not to treat.Chronic total occlusion: no more meta-analysis, please-a randomized clinical trial is urgently needed.Body mass index and hospital mortality in patients with acute coronary syndrome receiving care in a university hospitalPercutaneous coronary intervention of chronically occluded saphenous vein grafts using excimer laser atherectomy as an adjuvant therapy.Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients.Efficacy and safety of Tornus catheter in percutaneous coronary intervention of hard or balloon-uncrossable chronic total occlusion.Ischemic Heart Disease and Acute Cardiac Care 2015: A Selection of Topical Issues.P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes.Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.Outcomes with type 2 myocardial infarction compared with non-ischaemic myocardial injury.Embolization of a septal branch perforation using subcutaneous fat during a percutaneous coronary intervention of chronic total occlusion by retrograde approach.Cystatin C and cardiac hypertrophy in primary hypertension.Microalbuminuria in normotensive patients with autosomal-dominant polycystic kidney disease.[An unusual diagnostic technique of obstructive sleep apnoea syndrome].[Applicability of a new definition of myocardial infarction and the opinion of Spanish cardiologists].Prognosis and management of acute coronary syndrome in Spain in 2012: the DIOCLES study.New electrocardiographic criteria to differentiate acute pericarditis and myocardial infarction.[Characteristics and mortality following primary percutaneous coronary intervention for acute myocardial infarction in Spain. Results from the TRIANA 1 (TRatamiento del Infarto Agudo de miocardio eN Ancianos) Registry].Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome.[Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic kidney disease?].Usefulness of high-sensitivity troponin T for the evaluation of patients with acute chest pain and no or minimal myocardial damage.Variation and correlation of end-tidal CO2 and amplitude spectrum area in a refractory ventricular fibrillation. A case from the ReCaPTa study.No additional value of conventional and high-sensitivity cardiac troponin over clinical scoring systems in the differential diagnosis of type 1 versus type 2 myocardial infarction.Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD.Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction.Effects of anaesthesia on acute ischaemic arrhythmias and epicardial electrograms in the pig heart in situ.Troponin elevation in patients without acute coronary syndrome.
P50
Q28073338-FBB50531-6C3F-4D43-A845-988CACC3C844Q28085643-AEBCE649-0746-4D2F-AE34-21FAF70C53B0Q28196868-E9FE834E-B2DC-4522-AE95-6B581D73C1EAQ30542622-BF6889BC-701C-482D-AA9A-780FF04C19B9Q30544010-8CD66ED3-166E-4679-A67D-F36AF6EAD603Q30544638-BF004FE0-95B6-4A8B-B8C4-5B36AD02592FQ30572418-6766D681-BE4F-46BD-920C-43F7012F8E5CQ33163802-E63193CA-D436-4988-8DE3-91A598AFDDF4Q33572344-B37F7311-C4FC-431B-97A4-985946B66A0EQ33663481-917950C4-B0CA-440A-B41A-7EE1507DA395Q33882706-FEEC8B40-7FD2-44BF-A918-85250DD30A22Q33948505-05549532-FEEE-49AE-B21B-CC67F3DC458BQ36031834-70AEFE13-C30F-4007-B11A-A2D8F9386835Q36148198-390B2747-5B2D-499D-AFC8-3FF7455F1791Q36250165-A8BD08AA-0A0C-4205-A05E-C1D44CF4584DQ36843359-7909AADD-E3ED-4D84-92DA-99A88CA12841Q37606309-52930E60-01AA-44DD-AFC7-E98FAAE32FA8Q38763075-4B312543-4FFA-4C96-A794-1B4651CD50DEQ38830465-E49D4ED3-19BF-4EFE-9F79-25BE30A1B5D7Q38886447-66EE3586-D8C8-4091-A24D-D39F7FDF25B8Q39154873-BF46337C-CCEC-4C13-896B-2C0010F6CE9EQ39481709-7C23E402-74B1-4DEA-ACDD-FC31D8281EBBQ40541357-1368CE8E-B38D-4D10-9AFE-055E9885292DQ42085864-4E18905B-2F10-45E5-A639-51F78C49ED1CQ43180532-8D8E9FF4-6D06-4D84-B46D-1226E685AB77Q43917375-6E400CDC-21B0-4CA6-8FFB-30025127473DQ43966772-B34E9D8F-5FE8-4399-A907-CF10EA7ABEEEQ44292399-ACD0CDC4-852D-4C50-97F2-A9CBB1FC5A7CQ44357981-6F000AE2-82B7-4311-8E57-4F7CB9A79CBBQ44363001-7F3706B2-FB6F-4675-B631-68C989A0450DQ44377354-492A2291-EEE7-4EF4-873F-47C96B28B440Q44433622-CCD7FDBD-B90B-4983-AF3E-B025D8951C5AQ45953818-26DE0BBC-1DF1-4034-AD3C-762B2F89B415Q46328675-84616DC4-4615-4DA7-9E0A-80DC911B8E28Q47314546-EB99DBE2-603C-42FD-BECE-DE1227FC5ACFQ47663481-7F29A91A-EB1C-4B4E-8EEA-BFC93EAA942BQ48677154-F9DCB6BE-5640-427C-BDF2-7C84377F683FQ50867077-C38F15AD-8DB2-4E95-93EA-995BDD6D6F36Q51739478-C92D9E15-409E-47E7-A44C-3FE387921E31Q53777044-38A39716-C4B9-4FE4-A292-4D6975338EA1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alfredo Bardaji
@ast
Alfredo Bardaji
@en
Alfredo Bardaji
@es
Alfredo Bardaji
@nl
type
label
Alfredo Bardaji
@ast
Alfredo Bardaji
@en
Alfredo Bardaji
@es
Alfredo Bardaji
@nl
prefLabel
Alfredo Bardaji
@ast
Alfredo Bardaji
@en
Alfredo Bardaji
@es
Alfredo Bardaji
@nl
P106
P1153
7004218462
P21
P31
P496
0000-0003-1900-6974